A fresh nationwide effort spearheaded by the Kratom Research Institute (KRI) is calling on policymakers to safeguard access to natural kratom while addressing the risks posed by synthetic substitutes like 7-hydroxymitragynine (7OH). The campaign highlights concerns over synthetic 7OH products, which are being marketed as kratom in colorful tablets—often sold without proper regulation or age verification.
KRI’s executive director, Ryan Niddel, emphasized the group’s stance: “We’re not advocating for a kratom ban. Our goal is to ensure synthetic 7OH is regulated through established drug approval channels to protect public health.” Internal research from KRI reveals that the tiny amount of 7OH naturally found in kratom leaves cannot account for the quantities being sold, suggesting most of these products are artificially produced.
The organization is also collecting stories from consumers and healthcare professionals to better understand the impact of both natural and synthetic kratom. For the original article, visit The Herald Journal here.